share_log

恩华药业(002262.SZ):1类化学药品NH160030片获批开展临床试验

Jiangsu NHWA Pharmaceutical (002262.SZ): Type 1 chemical drug NH160030 tablets approved for clinical trials.

Gelonghui Finance ·  Nov 12, 2024 01:42

Gelonghui November 12th | Jiangsu NHWA Pharmaceutical (002262.SZ) announced that the company recently received the Approval Notice for Clinical Trial of Category 1 Chemical Drug NH160030 Tablet in 4 specifications issued by the National Medical Products Administration (referred to as the "NMPA"), and will conduct clinical trials in the near future.

NH160030 is an oral selective μ-opioid receptor agonist, a new generation of opioid analgesics. Preclinical trial results have shown that compared to commonly used opioid analgesics such as morphine and hydrocodone, it has superior efficacy and fewer side effects. NH160030 is derived from internal independent research and development, and the company exclusively owns its intellectual property. According to the requirements of China's drug registration laws and regulations, after obtaining the Approval Notice for Clinical Trial of the drug, clinical trials need to be conducted and approved by the NMPA before production and listing.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment